Lymphedema is a chronic disorder of impaired lymphatic drainage that leads to persistent limb or trunk swelling, hypertrophic adipose change, recurrent skin infections, impaired wound healing, and reduced quality of life. Both primary (congenital/ developmental) and secondary (acquired from trauma, infection, cancer surgery, or radiation) forms are described; clinically it is often characterized by non-pitting swelling and progressive tissue changes that may become refractory to conservative care. (See definitions for terminology and techniques.)
The established first-line treatment is conservative management with complete decongestive therapy (CDT), a multimodal regimen that includes compression garments, skin and wound care, limb compression (including pneumatic compression when indicated), manual lymphatic drainage, and exercise. CDT is the standard initial approach and must be documented as attempted when considering escalation to procedural options. Multiple guideline documents and consensus groups emphasize CDT and other non-surgical modalities as the foundational treatments for lymphedema.
A range of surgical procedures has been investigated for both treatment of established lymphedema and prevention at the time of oncologic lymph node dissection. These include: reductive/debulking procedures (liposuction / lipectomy, suction-assisted lipectomy) aimed at removing excess subcutaneous fat; microsurgical physiological procedures such as lymphaticovenous/lymphaticovenular anastomosis (LVA/LVB or lymphovenous bypass) and vascularized lymph node transfer (VLNT); and preventive microsurgical approaches performed at the time of lymph node dissection (LYMPHA / immediate lymphatic reconstruction/ILR). Techniques to identify and potentially preserve arm-draining nodes such as axillary reverse mapping (ARM) have also been studied, as have regional techniques like axillary or inguinal mapping and reconstruction.
The existing evidence is heterogeneous and often of low to moderate quality. Systematic reviews, health technology assessments, randomized trials, and observational series report potential reductions in limb volume, infection frequency, and patient-reported symptom burden for select procedures (for example, liposuction plus lifelong compression in fat‑dominant disease; LVA and VLNT in earlier-stage lymphedema), and several meta-analyses indicate lower incidence of secondary lymphedema with some immediate reconstruction approaches. However, studies vary widely in patient selection, surgical technique, outcome measurement, and follow-up duration, limiting generalizability and certainty about durable benefit.